Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.77 |
| ▸ | HPGD | P15428 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | HPGDS | O60760 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asengeprast SCHEMBL31143704 | 1.00 | ALDH1A1 (0.77) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| Asengeprast SCHEMBL29363682 | 1.00 | ALDH1A1 (0.77) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| Asengeprast SCHEMBL1590608 | 1.00 | ALDH1A1 (0.77) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2842999 | 0.96 | MEN1 (0.77) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2843001 | 0.96 | MEN1 (0.77) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL20456019 | 0.91 | ALDH1A1 (0.63) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2871410 | 0.91 | TRPA1 (0.72) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2839384 | 0.90 | MEN1 (0.74) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL2839387 | 0.90 | MEN1 (0.74) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL16215173 | 0.90 | ALDH1A1 (0.61) | ALDH1A1HPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262785-A1 | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2024-08-08 | — | — | US | disclosed |
| US-11905231-B1 | Solid forms, salts and polymorphs of anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2024-02-20 | — | — | US | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-2947073-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2019-04-03 | — | — | EP | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| EP-2799427-A1 | Therapeutic compounds | Fibrotech Therapeutics PTY LTD (AU) | 2014-11-05 | — | — | EP | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-12-19 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| EP-2491030-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047432-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-04-28 | — | — | WO | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | ALDH1A1 1066/4885HPGD 612/4885MEN1 4394/4885 |
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | ALDH1A1 1274/4885HPGD 553/4885MEN1 3362/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | ALDH1A1 1274/4885HPGD 553/4885MEN1 3362/4885 |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | ALDH1A1 1066/4885HPGD 612/4885MEN1 4394/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | ALDH1A1 1184/4885HPGD 522/4885MEN1 3342/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | ALDH1A1 199/4885HPGD 536/4885MEN1 2640/4885 |
| US-11905231-B1 | Solid forms, salts and polymorphs of anti-fibrotic compounds | COL2A1, COL1A1, FIBP | ALDH1A1 728/4885HPGD 701/4885MEN1 4724/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | ALDH1A1 1967/4885HPGD 558/4885MEN1 2379/4885 |
| US-20240262785-A1 | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | COL2A1, COL1A1, FIBP | ALDH1A1 728/4885HPGD 701/4885MEN1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.